The speed of enrollment of the trials is crucial t

The speed of enrollment of the trials is crucial to quicker approval unless the FDA accepts data from the EIND patients. NP said this last week that enrollment was initially slow because protocols at each hospital had to be established. My hope is that enrollment has sped up over the past week, but I’m not sure if or when we’ll know how true that is.

The 390 patient severely ill trial is my concern in terms of enrollment and data. I don’t recall NP mentioning this last week that a patient had been enrolled yet. I’d expect this trial to fill quickly, considering how many people are dying each day, but who knows how many hospitals are participating and where those hospitals are.

The mild to moderate trial should enroll quickly. It’s a small trial of only 75 patients and is taking part in a large hospital network in the south east. I’d expect that trial to be fully enrolled by this week, if not sooner, but that may be overly optimistic. The downside to this trial is that endpoints are assessed at 6 weeks.